Clarion News

Clarion, a life sciences strategy and organizational consultancy, will lead a panel discussion titled, “Lessons From Emerging Biopharma Companies Commercializing Their First Asset” at the upcoming ExL Pharma New Product Planning Summit on December 13th.

The discussion—which will be moderated by Clarion managing director and founder, Bart Lombardi—will share perspectives on new enterprise commercialization (NEC) and incorporate highlights from Clarion’s recent NEC survey analyzing valuable insights and best practices from leaders in the industry.

Three esteemed thought leaders in the commercialization space will join the panel, including:

• Sarah Kurz, Chief Commercial Officer at Partner Therapeutics
• John Garcia, Global Commercial Excellence Lead at Alnylam Pharmaceuticals
• Scott T. Megaffin, Chief Executive Officer at Tragara Pharmaceuticals Inc.

The panel will take place from 11:15 am – 12:15 pm in the Westminster room at the Hilton Boston Back Bay. Register to attend the New Product Planning Summit here. For more information on Clarion’s work in new product commercialization, please see the “Our Work” section of our website.

About Clarion

Clarion is a life sciences strategy and organizational consultancy that works together with its clients to envision, craft, and enable growth through innovation and leadership. Across therapeutic categories, Clarion collaborates deeply with its clients to tackle their most complex cross-functional business challenges and decisions throughout the product and company lifecycle. With over 15 years of unparalleled experience in new product commercialization, Clarion partners with leaders in the biopharma industry to guide strategic decision-making necessary to launch a first asset or expand an existing portfolio.